Link to this page
Physician Data Query
| Preferred Name | diflunisal | |
| Synonyms |
(1,1'-biphenyl)-3-carboxylic acid, 2',4'-difluoro-4-hydroxy- Novo-Diflunisal Apo-Diflunisal Dolobid Flovacil 2',4'-difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid Nu-Diflunisal |
|
| Definitions |
A difluorophenyl derivate of salicylic acid and a nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic and anti-inflammatory properties. Diflunisal competitively inhibits both cyclooxygenase (COX) -1 and -2, with higher affinity for COX-1, and subsequently blocks the conversion of arachidonic acid to prostaglandin precursors. This leads to an inhibition of the formation of prostaglandins that are involved in pain, inflammation and fever. Diflunisal differs from other salicylates, in that it is not metabolized to salicylic acid, hence it has a longer half-life. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47489" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47489" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000691337 |
|
| altLabel |
(1,1'-biphenyl)-3-carboxylic acid, 2',4'-difluoro-4-hydroxy- Novo-Diflunisal Apo-Diflunisal Dolobid Flovacil 2',4'-difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid Nu-Diflunisal
|
|
| CAS Registry |
22494-42-4
|
|
| cui |
C1569311 C1569310 C1707746 C0012228 C1569312 C0699201
|
|
| DATE FIRST PUBLISHED |
2010-12-15
|
|
| Date last modified |
2010-12-15
|
|
| definition |
A difluorophenyl derivate of salicylic acid and a nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic and anti-inflammatory properties. Diflunisal competitively inhibits both cyclooxygenase (COX) -1 and -2, with higher affinity for COX-1, and subsequently blocks the conversion of arachidonic acid to prostaglandin precursors. This leads to an inhibition of the formation of prostaglandins that are involved in pain, inflammation and fever. Diflunisal differs from other salicylates, in that it is not metabolized to salicylic acid, hence it has a longer half-life. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47489" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47489" NCI Thesaurus)
|
|
| LT |
TRD
|
|
| NCI ID |
C47489
|
|
| notation |
CDR0000691337
|
|
| ORIG STY |
Drug/agent
|
|
| prefLabel |
diflunisal
|
|
| tui |
T109 T121
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |